PMID- 27080343
OWN - NLM
STAT- MEDLINE
DCOM- 20171120
LR  - 20171202
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
VI  - 6
IP  - 9
DP  - 2016 Sep
TI  - Effects of a honeybee lactic acid bacterial microbiome on human nasal symptoms, 
      commensals, and biomarkers.
PG  - 956-63
LID - 10.1002/alr.21762 [doi]
AB  - BACKGROUND: Lactic acid bacteria (LAB) can restore commensal microbiomes and 
      prevent infections. Arguably, nasal administrations of LAB may therefore be 
      beneficial in chronic rhinosinusitis (CRS). Previous studies have examined 
      effects of topical/nasal LAB in children with secretory otitis media, but little 
      is as yet known about their effects on the human nasal airway. The aim of this 
      pilot study was to examine effects on nasal symptoms and commensal bacteria in 
      healthy subjects of nasal administration of a honeybee LAB microbiome; ie, a 
      mixture of 9 Lactobacillus spp. and 4 Bifidobacterium spp. obtained from the 
      honeybee Apis mellifera. Furthermore, we aimed to assess whether or not the 
      honeybee LAB produced a local inflammatory response. METHODS: Twenty-two healthy 
      subjects received a single administration of honeybee LAB in a sham-controlled, 
      double-blinded, and crossover design. Using questionnaires, microbiological 
      methods, and nasal lavages, they were assessed regarding symptoms, changes to 
      commensal bacteria, and inflammatory products in nasal lavage fluids. RESULTS: 
      The honeybee LAB did not produce any symptoms or other untoward effects. No 
      changes were observed of commensal bacteria by the honeybee LAB, and no 
      inflammatory response was detected (compared to sham); ie, unaffected nasal 
      lavage fluid levels of monocyte chemoattractant protein-1 (MCP-1), interleukin-8 
      (IL-8), monokine induced by interferon-gamma (MIG), interleukin-15 (IL-15), epidermal 
      growth factor (EGF), eotaxin, interferon gamma-induced protein-10 (IP-10), and 
      interleukin-1 receptor antagonist (IL-1RA). CONCLUSION: A single human nasal 
      administration of a honeybee LAB microbiome is well tolerated. Specifically, it 
      does not affect commensal bacteria and does not produce an inflammatory response.
CI  - (c) 2016 ARS-AAOA, LLC.
FAU - Martensson, Anders
AU  - Martensson A
AD  - Department of Otorhinolaryngology (ORL), Helsingborg Hospital, Helsingborg, 
      Sweden.
FAU - Greiff, Lennart
AU  - Greiff L
AD  - Department of ORL-Head and Neck Surgery, Skane University Hospital, Lund, Sweden. 
      lennart.greiff@skane.se.
FAU - Lamei, Sepideh S
AU  - Lamei SS
AD  - Department of Laboratory Medicine, Lund, Section of Medical Microbiology, Lund 
      University, Lund, Sweden.
FAU - Lindstedt, Malin
AU  - Lindstedt M
AD  - Department of Immunotechnology, Lund University, Lund, Sweden.
FAU - Olofsson, Tobias C
AU  - Olofsson TC
AD  - Department of Laboratory Medicine, Lund, Section of Medical Microbiology, Lund 
      University, Lund, Sweden.
FAU - Vasquez, Alejandra
AU  - Vasquez A
AD  - Department of Laboratory Medicine, Lund, Section of Medical Microbiology, Lund 
      University, Lund, Sweden.
FAU - Cervin, Anders
AU  - Cervin A
AD  - Department of ORL-Head and Neck Surgery, Royal Brisbane and Women's Hospital, 
      School of Medicine, University of Queensland, Brisbane, Australia.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160415
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
SB  - IM
MH  - Administration, Intranasal
MH  - Adult
MH  - Animals
MH  - *Bacteria/isolation & purification
MH  - Bees/*microbiology
MH  - Biomarkers
MH  - Cross-Over Studies
MH  - Cytokines/immunology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - *Microbiota
MH  - Nasal Lavage Fluid/immunology/microbiology
MH  - Young Adult
OTO - NOTNLM
OT  - SNOT-22
OT  - bacterial interference
OT  - bacteriology
OT  - bifidobacteria
OT  - lactobacillus
OT  - paranasal sinuses
OT  - probiotics
OT  - therapeutics
EDAT- 2016/04/16 06:00
MHDA- 2017/11/29 06:00
CRDT- 2016/04/16 06:00
PHST- 2015/09/22 00:00 [received]
PHST- 2016/01/05 00:00 [revised]
PHST- 2016/02/04 00:00 [accepted]
PHST- 2016/04/16 06:00 [entrez]
PHST- 2016/04/16 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - 10.1002/alr.21762 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2016 Sep;6(9):956-63. doi: 10.1002/alr.21762. Epub 2016 
      Apr 15.